New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Northwell Health Imbert Cancer Center, Bay Shore, New York
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Evaluating BOSCC and ELSA as Outcome Measures in the Context of a JASPER Intervention Trial
Recruiting
Research teams in Boston University, UCLA, and Weill Cornell will recruit 90 participants in 3 years (10 participants per site per year) and evaluate JASPER, play-based intervention, using the BOSCC and ELSA-T. Participants will be randomized to receive JASPER facilitated either by a clinician or the caregiver. After 10 weeks, the participants will be evaluated using the CGI to determine if they are "responders" or "non-responders". Nonresponders will be given a mix of clinician and caregiver-fa... Read More
Gender:
ALL
Ages:
Between 18 months and 5 years
Trial Updated:
03/04/2025
Locations: Weill Cornell Medical College/New York Presbyterian Hospital, White Plains, New York
Conditions: Autism Spectrum Disorder
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
Recruiting
This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Conditions: Advanced Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
Recruiting
This phase III trial studies how well radiation therapy with protons works compared with photons in treating patients with liver cancer. Radiation therapy, such as photon therapy, uses high energy x-rays to send the radiation inside the body to the tumor while proton therapy uses a beam of proton particles. Proton therapy can stop shortly after penetrating through the tumor and may cause less damage to the surrounding healthy organs and result in better survival in patients with liver cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Memorial Sloan Kettering Commack, Commack, New York
Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Unresectable Hepatocellular Carcinoma
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Recruiting
This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York
Conditions: Intracranial Meningioma, Grade 2 Meningioma
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Recruiting
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only), Commack, New York
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
Recruiting
The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack, New York
Conditions: Diarrhea, Enterocolitis
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Recruiting
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities), Commack, New York
Conditions: T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma, T-cell Leukemia, Lymphoma
JAG201 Gene Therapy Study in Children & Adults with SHANK3 Haploinsufficiency
Recruiting
This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (ICV) injection in pediatric and adult participants with SHANK3 haploinsufficiency resulting from SHANK3 loss of function mutations and chromosomal deletions encompassing the SHANK3 gene. Clinical data will be evaluated for safety, tolerability, and preliminary clinical activity of JAG201 in pediatri... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
03/03/2025
Locations: Seaver Autism Center at Mount Sinai, New York City, New York
Conditions: SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Recruiting
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the metastatic sett... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Clinical Research Alliance, Westbury, New York
Conditions: PD-L1-positive Metastatic NSCLC
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Recruiting
Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced or metastatic HER2-altered NSCLC. Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: New York Medical College /ID# 265799, Valhalla, New York
Conditions: Diffuse Large B-Cell Lymphoma